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AIDS-Associated Viral Oncogenesis
1. OVERVIEW
Charles Wood, Ph.D.
Nebraska Center for Virology and the School of Biological Sciences, 
University of Nebraska, Lincoln, Nebraska, USA
It has been 25 years since the acquired immunodeficiency syndrome (AIDS) was first de-
scribed and over 23 years since the human immunodeficiency virus (HIV) associated with 
the disease was first discovered. In spite of the tremendous progress that was made in un-
derstanding both the disease and the virus, there are still millions of people infected, died, 
or living with the disease. As for the year 2005 alone, the Joint United Nations Programme 
on HIV/AIDS (http://www.UNAIDS.org) estimates that there are about 40 million peo-
ple living with HIV/AIDS globally, and approximately 3 million people died from AIDS 
in the year. Globally, it is estimated that 25 million people have died of HIV/AIDS since 
1981. The impact of the epidemic is enormous, with the greatest impact in sub-Saharan Af-
rica where about two-thirds of those living with HIV/AIDS in the world reside. A number 
of countries in the region have infection rates to as high as 30-40% of the population. As 
for South and Southeast Asia, even though the adult prevalence is lower and estimated to 
be less than 1%, there are still 7.4 million people living with HIV/AIDS in this region, ac-
counting for about 18% of those living with HIV/AIDS in the world.104,114 North America, 
Latin America, and Eastern Europe and Central Asia, each have between 1.2 and 1.8 mil-
lion people living with HIV/AIDS. Although the 300,000 people living with HIV/AIDS in 
the Caribbean constitute a small part of the global total, they are about 1.6% of adults in 
the region, making the Caribbean the only region other than sub-Saharan Africa to have 
an adult prevalence higher than 1%.104,114 Essentially, no single country can escape from 
the impact of HIV/AIDS.
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Since the beginning of the AIDS epidemic, it was soon realized that HIV-infected indi-
viduals that are immunosuppressed are affected not only by opportunistic infections but 
also by other AIDS-associated diseases, including malignancies. In fact, at the onset of 
the AIDS epidemic in 1981, the disease was first recognized through an increase of Kapo-
si's sarcoma (KS) in young adult homosexual male population, which is unusual as KS is 
a very rare form of malignancies which are found in certain ethic groups in the Mediter-
ranean region and in Africa.29,57 In 1992, the US Center for Disease Control and Preven-
tion (CDC) developed the initial case definition for AIDS and included two AIDS-defining 
malignancies, KS and primary central nervous system lymphoma (PCNSL).2 It was soon 
realized that patients infected by HIV are also at risk for developing both Hodgkin's and 
non-Hodgkin's lymphomas (NHL) when compared to normal uninfected individual, with 
a large number of homosexual male with AIDS developed NHL.122 Subsequently, CDC 
has revised the definition of AIDS to include NHL in 19871 and invasive cervical cancer 
in 1992.3 In addition to the common AIDS-defining malignancies it has been reported that 
AIDS and or immunosuppression may lead to an increase in other non-AIDS defining can-
cers, including multiple myeloma, Hodgkin's disease, leukemia, lung cancer, oral cavity 
cancers, and leiomyosarcoma in children.44,47 These malignant tumors are generally char-
acterized by a more aggressive behavior at diagnosis and a poorer outcome compared with 
the same tumors in the general population. A large-scale study by Frisch et al.34 analyzing 
cancer registries from 11 sites in the US for over 300,000 HIV-infected adults showed that 
these individuals have a very high risk in developing AIDS-defining cancers, but in addi-
tion, non-AIDS defining cancers also showed a statistically significance increase as well. 
Those that showed a potential association with immunosuppression are Hodgkin's dis-
ease (HD), lung cancer, penile cancer, soft tissue malignancies, and testicular seminoma. 
However, most non-AIDS-defining cancers do not appear to be associated with HIV-asso-
ciated immunosuppression and disease progression.36,80 It is likely that other factors could 
be involved, including smoking and other viral coinfections.
A number of the common cancers associated with AIDS and immunosuppression were 
found to have infectious viral cofactors, including those classified as AIDS-defining disease, 
KS, NHL, and invasive cervical cancers. Kaposi's sarcoma and primary effusion non-Hodg-
kin's lymphomas have been linked to Kaposi's sarcoma-associated herpesvirus (KSHV) or 
human herpesvirus-8 (HHV-8); Hodgkin's disease and non-Hodgkin's lymphomas have 
been linked to EBV; and squamous cell carcinomas have been linked to human papilloma 
virus (HPV) (Table 1).These viral-associated AIDS-malignancies will be the major focus of 
this chapter.
AIDS-ASSOCIATED KAPOSI'S SARCOMA
KS is a very rare form of sarcoma that has become the most common neoplasm in HIV-in-
fected individuals, since the onset of the AIDS epidemic. KS was first described by Moritz 
Kaposi in 1872 as an indolent tumor in elderly Mediterranean men with multifocal pig-
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Table 1. AIDS-associated malignancies with viral etiology
Malignancies Virus
Kaposi’s sarcoma Human herpesvirus-8 (HHV-8) or 
Kaposi’s sarcoma-associated 
herpesvirus (KSHV)
Non-Hodgkin’s lymphomas
     Primary central nervous system lymphoma Epstein-Barr Virus (EBV)
     Primary effusion lymphoma HHV-8
     Burkitt’s lymphoma EBV
Plasmabalistic lymphoma EBV
Hodgkin’s disease EBV
Squamous cell neoplasm
     Genital dysplasia
HPV
mented sarcoma.62 KS is composed of a mixture of irregular shaped, round capillaries, and 
slitlike endothelium-lined vascular spaces and spindle-shaped cells with infiltrating mono-
nuclear cells. It is not clear whether KS represents a clonal neoplastic process or a polyclonal 
inflammatory lesion. Studies have shown that varying monoclonality, oligoclonality, and 
polyclonality from lesions of various patients.40 The origin of KS spindle cells is also not clear; 
it has been suggested that KS cells represent a heterogeneous population of cells, arising from 
pluripotent mesenchymal precursor cells, and may be of lymphatic endothelial cell origin.28
Since AIDS was first described in the early 1980s, the annual incidence of KS in the San 
Francisco Bay area showed an exponential increase with the incidence rate per age group 
followed a bimodal distribution that peaks from 30 to 36 years of age.24 KS has become the 
most common neoplasm in HIV-infected individuals, and has reached epidemic proportions 
in the developing world where HIV is widespread, such as sub-Saharan Africa. Patients in 
this region with AIDS-associated KS have been shown to have a high tumor burden and 
rapid disease course, very different from those seen in the non-AIDS-related KS. There are 
four different epidemiological forms of KS that showed different clinical parameters. The 
first is the classical or sporadic form of KS. This is associated with elderly men in the Medi-
terranean countries like Italy and Israel.57 This form of KS is usually nonaggressive and as-
sociated with lesions in the lower extremities. It is usually not associated with HIV infection. 
The older the patients are, the risk for disease progression is also greater, and disseminated 
KS in these individuals could occur if they are immunosuppressed. The second form of KS is 
endemic African KS. This form of KS was found in the African continent prior to the onset of 
the AIDS epidemic. It is found not only in men but in women and young children as well.117 
This form of KS tends to be more aggressive than the classical KS and can also involve the 
lymph nodes. With the spread of HIV since the 1980s, the prevalence of KS in the African 
continent has increased substantially. A study in Uganda has shown that prior to the 1970s, 
KS was diagnosed in no more than 7% of the male cancer population, and none in the female.
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However, by the early 1990s, it had risen to around 49% of the male cancer patients, and 
18% of the female cancer patients.117 and similar increases were reported in other African 
nations. In Zambia, in the late 1990s, KS was found to be one of the most common child-
hood cancers.16 most likely due to HIV coinfection.The third type of KS is the Iatrogenic KS 
or transplant-associated KS. This normally occurs in patients after transplantation that were 
treated with irnmunosuppressive drugs, and withdrawal of therapy can lead to KS regres-
sion.53 This form of KS tends to have a more rapid disease course as compared to the classi-
cal KS, but can also present as a chronic condition.53 The fourth form of KS is the AIDS KS. 
This form of KS has been found to be associated with AIDS patients, it has increased dra-
matically since the onset of the AIDS epidemic and is one of the AIDS-defining illnesses.43,45 
This is the most aggressive form of KS and was first described in the early 1980s in the HIV-
infected homosexual male population.33 Unlike the classical KS, AIDS KS involves not only 
the lower extremities and skin, but also the upper body, the head regions, and the lymph 
nodes. It can also disseminate to other organs, such as the spleen, the lungs, the liver, and 
gastrointestinal track.53
Human Herpesvirus and KS
An infectious agent has long been suspected in the development of KS; herpesvirus-like 
particles were found in short-term KS tissue culture, and were subsequently identified as cy-
tomegalovirus,41 but the involvement of CMV in KS has not been confirmed. In 1994, a novel 
human herpesvirus was identified by Chang and Moore14 using representational difference 
analyses. This virus is now known as KSHV or HHV-8 and is found to be necessary, but not 
sufficient for the development of all types of KS. It is clear that other cofactors, such as im-
munosuppression, are required for KS development. KSHV is found in all KS lesions, and 
is mainly located in the vascular endothelial cells and perivascular spindle-shaped cells75 
KSHV infection is not commonly found in low-risk population but found commonly in in-
dividuals at risk for KS.
KSHV belongs to the γ-herpesvirus family, which can further be divided into two sub-
groups, γ-1 or lymphocrytovirus and γ-2 or rhadinovirus. EBV is the prototype of γ-1 vi-
rus and the simian herpesvirus saimini is the prototype of γ-2 herpesvirus.96 KSHV is clas-
sified as a γ-2 rhadinovirus and is the first human virus of this subfamily identified. Like 
other herpesviruses, HHV-8 is a double-stranded deoxyribonucleic acid (DNA) virus. Its ge-
nome is linear, it is about 165 kbp in length, and contains at least 87 viral genes. A feature of 
some DNA viruses, particularly of herpesviruses and KSHV, is the ability of these viruses 
to incorporate or pirate host genes into their genome: these genes can then play a role in the 
replication, survival, and transformation functions of the virus. KSHV was found to encode 
human homologous genes that regulate cell cycling like cyclin D, growth factors like inter-
leukin 6, or genes that may prevent programmed cell death such as bcl-2. Deciphering the 
functions of these viral genes will lead to a better understanding of viral pathogenesis and 
oncogenesis.
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Unlike most other herpesviruses, KSHV infection does not seem to be widely distributed 
in most populations. The detection of KSHV infection relies on the presence of antibodies 
against either lytic and/or latent antigens and varies among the different tests that were 
used in different seroprevalence studies. In general, the frequency of infection appears to 
be low in North America, certain Asian countries, and in Northern European nations such 
as the UK and Germany, with most studies reporting a seroprevalence rate in normal blood 
donors of less than 5%.30,88,99,100 In these countries the seroprevalence of KSHV in different 
risk groups mirrors the incidence of AIDS KS, with a seroprevalence rate of 25-50% among 
homosexual men. In other countries, such as Italy, Greece, and Israel, especially Southern It-
aly, the infection rate seems to be much higher in the general population, and is more vari-
able, ranging between 5 and 35%. In contrast to North America and Europe, KSHV infec-
tion is widespread in the African continent. High seroprevalence rates between 40 to 50% 
have been found in Central, West, and South Africa.6,37,50,86 Therefore, KSHV seroprevalence 
tracks very closely with KS, with the highest infection rate in geographic areas where clas-
sic or endemic forms of KS are more common. KS has a particularly high incidence in Cen-
tral African countries like the Republic of Congo, Uganda, and Zambia; these countries also 
have the highest KSHV infection rates in the world.37 Very little is known about KSHV infec-
tion in China even though EBV infection was found to be ubiquitous. There were only two 
reported studies in China; Dilnur et al.23 found that KSHV was associated with KS in China. 
The study by Du et al.26 in the outskirts of China in the Xinjiang autonomous region, where 
there is a high incidence of HIV-1 infection, showed that there was a high KSHV infection 
rate. The study found KSHV infection varied among individuals of different racial origin, it 
was highest in the Khalkhas population at about 48% and lowest in the Kazak and Han pop-
ulation at over 12%, but the specimens were screened without dilution, the reproducibility 
of the assay was not determined, and the prevalence among different risk groups was not 
studied. Thus, there is a need to perform a systematic comparison of risk groups using es-
tablished assays.
Impact of HAART on KS
Since the beginning of the AIDS epidemic in the early 1980s, AIDS KS has become one of 
the most common AIDS-associated malignancies with HIV-infected homosexual males at 
the highest risk, and those with AIDS had a 50% lifetime rate of developing KS early in the 
HIV epidemic.63 However, the rate of AIDS KS has since steadily declined both in the US 
and Europe.7 It has been suggested that the disease may have shifted from an early disease 
to a late manifestation during the HIV disease course. Since the introduction of highly ac-
tive antiretroviral therapy, a further major decrease in AIDS KS was further observed.71 and 
therapy has now made AIDS KS a relatively rare tumor in treated HIV-infected individuals.9 
Several studies have shown that there was a marked decrease in KS incidence since HAART 
was introduced, a decline of as high as 80-fold was observed. In addition, regression of 
KS following treatment has been reported.48,58,91,92,112 Interestingly, the reduced KS risk was 
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only observed with HAART, but not with double or single anti-HIV drugs.59 Even though 
the incidence of KS in the treated HIV-infected individuals in the western world has de-
creased dramatically, in the setting where HAART is still not widely available, such as sub-
Saharan Africa, AIDS KS still remains a major problem.
AIDS-ASSOCIATED NON-HODGKIN'S LYMPHOMA
ARL represents a heterogeneous group of tumors that are commonly found in HIV-in-
fected, immunosuppressed individuals. The majority of the cancers are of B-cell in origin; 
the development of these cancers is characterized as an AIDS-defining illness.68,74 ARL in 
general is a late event in the HIV disease course. The risk factors for the development of 
ARL include low CD4 and T cell counts, high HIV viral load, and increased age.66 ARL 
in general is classified into three groups. The first are those that can also be found in im-
munocompetent individuals, like Burkitt's lymphoma (BL) and diffuse large B-cell lym-
phoma (DLBCL) which can further be classified into centroblastic, immunoblastic, and 
anaplastic subtypes. An example of DLBCL is the primary central nervous system lym-
phoma (PCNSL), which is a distinct extranodal presentation of DLBCL.68 The second are 
those that are found only in HIV-infected immunosuppressed individuals. They include 
the primary effusion lymphoma (PEL) and plasmablastic lymphoma. The third are those 
that can be found also in immunosuppressed patients other than those due to HIV infec-
tion. These include post-transplant lymphoproliferative disorders. In general, the differ-
ence between ARL and NHL found in non-AIDS-associated patients is the presentation of 
advanced diseases, extranodal involvement, disease in soft tissues, and other locations, 
such as jaws and their association with viral infections, most prominently EBV and KSHV 
In addition to viral coinfections, a large proportion of the ARL also have genetic abnor-
malities, especially among the large-cell lymphomas, Bcl-6 rearrangement occur in about 
33% of the cases, c-myc rearrangement about 40%, and p53 mutations about 25% of the 
cases,35 whether these genetic abnormalities are the causes or effect of malignant transfor-
mation is not clear.
The most commonly identified virus associated with AIDS-related lymphomas is EBV and 
there is a large body of published work on the oncogenic mechanisms of this agent.12, 121 The 
second most common is KSHV, which was found to be associated with PEL associated with 
HIV infection.13' B-lymphocytes transformed by EBV (lymphoblastoid cell lines) in vitro ex-
press an array of virus-encoded proteins including six EBV nuclear antigens (EBNAs) and 
three LMPs. EBNAs are generated from differential splicing of a transcript that arises from 
one of two promoters (Cp or Wp).121 This form of latency is termed Latency III, and is com-
mon in immunoblastic lymphomas.12 A Type II form of latency where EBNA 1, LMP-1, and 
LMP-2a are expressed has been identified in some EBV-associated lymphomas. In Latency I 
(typical of Burkitt's lymphomas) only EBNA-l (generated from the Qp promoter) and EBV-
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encoded RNAs (EBERs) are expressed.12,121 Recent studies have indicated that some hetero-
geneity in EBV gene expression and EBNA promoter usage exists among endemic BL.65 It 
has been proposed that classical antigen driven B-cell proliferation may play a role in the 
ARL.68 The hyperstimulation of B lymphocytes could be caused by HIV, EBV, and other in-
fectious agents that may elicit the release of various growth factors and cytokines which pro-
mote the proliferation and transformation of B cells into ARC.
Among the ARL, the ones most commonly found in HIV-infected individuals are BL and 
DLBCL. They represent about 90% of all ARLs.8 The others, such as PEL, represent less than 
50% of the cases. Chemically immunosuppressed individuals, like those infected with HIV, 
have a much higher risk of developing lympho-proliferative disorders. The increased risk of 
developing ARC has been reported to range from 14-fold for low-grade lymphoma to 630-
fold for high-grade immunoblastic lymphoma.21 A study by Cote et al. has shown that the 
risk of HIV-infected individuals developing ARL within 3 years of being diagnosed with 
AIDS was 165-fold higher than those without AIDS. The same study also showed that the 
risk of developing BL is 261-fold higher.20 In addition, it has been demonstrated that risk of 
AIDS patients developing PCNSL is 3,000 times higher and HD is ten times higher than HIV 
uninfected individuals.108
Burkitt's Lymphoma AIDS-related BL is one of the most common ARLs found in HIV-in-
fected individuals. Unlike other ARL, BL is unique in that presentation of the cancer can oc-
cur at relatively high CD4 T-cell count (>250 cells/mm3).90 AIDS BLs share features with en-
demic African BL in that both over express c-myc due to reciprocal translocations that bring 
the transactivator under the influence of potent promoter sequences within the immuno-
globulin (Ig) genes loci. Inactivating mutations and deletions of p53 are also common as in 
all types of BL,11 but Bcl-6 rearrangements are rarely observed. A distinguishing feature be-
tween AIDS-related and endemic BL is that the former is associated with EBV far less fre-
quently than the latter.11,72 EBV has been reported to present in a subset of between 33 and 
67% of these AIDS-related BL, and the type III latency expressing viral EBNAs and LMP pro-
teins was not consistently observed. With some expressing viral antigen patterns that are 
similar to those seen in Hodgkin's disease.103 BL often carry genetic abnormities and chro-
mosomal translocation, but there is no evident that EBV has been linked to these abnormal-
ities, c-myc translocation is common in BL, with the c-myc gene transposed to the proxim-
ity of the immunoglobulin locus, and often led to the activation of c-myc expression. These 
tumors are incredibly aggressive with short doubling times. Flow cytometric analysis typi-
cally reveals that over 90% of the tumor cells are in S phase. Ongoing tumor lysis syndrome 
even in the absence of concomitant chemotherapy is often noted. AIDS-related BLs appear 
to carry a poor prognosis even when compared to AIDS-related DLBCL.77
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Primary Central Nervous System Lymphoma
Primary central nervous system lymphoma (PCNSL) is a distinct extranodel form of DL-
BCL, which is usually of the immunoblastic type. It is a rapid and fatal disease with poor 
prognosis, associated with HIV infection and severe immunodeficiency, usually with CD4+ 
T cell counts of < 50 cells/mm3.85,107 HIV-infected persons with PCNSL usually have tumors 
confined to the craniospinal axis without systemic involvement. In contrast to PCNSL in 
HIV negative individuals, those found in the context of HIV infection is always associated 
with EBV in HIV-infected patients.85 Detection of EBV sequences in the CSF by polymerase 
chain reaction in combination with thallium spectroscopy has been shown to be a useful di-
agnostic tool for the disease.17 Since EBV is always present in PCNSL, it is likely that this vi-
rus plays a role in cancer development. The EBV genes that are expressed include the latent 
gene. EBNAs and LMP-1 and -2, typical of a type III latency seen in B cells, when they are 
transformed by EBV in vitro.120 These EBV genes, such as LMP-2, are known to deregulate 
cellular replication and may play a role in the transformation of B cells. These gene products 
are also good targets of cytotoxic T lymphocytes, which could account for the reduction of 
PCNSL in patients that were undergoing antiretroviral therapy (ART) when their cytotoxic 
lymphocyte response was restored. However, it has been reported that abnormalities in the 
T cell functions in these patients can still be observed.116 Thus, other factors, including the al-
ternation of the EBV gene expression profile could have occurred upon ART. Treatment of pa-
tients with PCNSL with conventional chemotherapy in combination with radiation therapy 
has not been very effective. Only a 4-month survival has been observed. However, treatment 
with a high dose of zidovudine and ganciclovir has been shown to lead to long-term remis-
sion,93,98 again suggesting that therapy targeting EVB may be effective in controlling PCNSL.
Plasmablastic Lymphoma
Plasmablastic lymphoma is a recently described variant form of ARL that only occurs in a 
low percentage of HIV-infected individuals. It was originally described by Delecluse et al. as 
a B-cell lymphoma stained by antibody specific for plasma cells, but these cells lack the clas-
sical I3-cell antigen CD20.22 These cancers occur only in a small percent of HIV-infected pa-
tients and are usually associated with EEV and KSHV infection.11 Patients usually develop 
tumors in the jaw and oral cavity and the prognosis is poor. Patients with plasmablastic lym-
phoma normally do not respond to conventional chemotherapy and it has been suggested 
that therapy targeting EBV may be beneficial.18 In fact, ART and intensive chemotherapy has 
been shown to be encouraging as five out of six HIV-infected and treated individuals were 
alive with a medium follow-up of 17 months.113
Primary Effusion Lymphoma
Primary effusion lymphoma (PEL) is a very rare subtype of NHL, predominantly associ-
ated with HIV-infected individuals. PEL was first identified as a subset of body-cavity-based 
lymphomas, which were subsequently called PELs.13 PELs are unique as they were found to 
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contain KSHV DNA and are most frequently found in men and in AIDS patients. This type 
of lymphoma is distinguished from others as having a distinctive morphology, bridging 
large cell immunoblastic lymphoma and anaplastic large cell lymphoma. PELs often present 
as lymphomatous effusions in the pleural, peritoneal, and/or pericardial cavity. These cells 
are usually CD20 negative, often express CD45 marker but lack 13-cell-associated antigens. 
PELs have 13 cell origins with clonal immunoglobulin gene rearrangements. Gene expres-
sion profiling of PEL by Klein et al. 67 showed that PEL displayed a common gene expression 
profile that is distinct from ARL and NHL in HIV uninfected individuals. The profile also 
showed elements seen in EBV transformed lymphoblastoid cell lines, AIDS immunoblastic 
lymphoma, as well as multiple myeloma. Further confirming the notion that PEL is distinct 
and yet a subtype of NHL. Most PELs are coinfected with EBV and KSHV and lack e-myc 
gene rearrangements. PELs are extremely rare tumors, and estimated to be about 0.13% of 
all AIDS-related malignancies in AIDS patients in the US.80 Thus, KSHV-associated lympho-
mas represent a rare, distinct pathobiologic category which often, but not always, associates 
with an effusion in AIDS patients. The role of KSHV in the development of these lympho-
mas is not clear since this type of malignancies is still rare even in the populations with high 
KSHV seroprevalence rate. However, KSHV has always been found in these lymphomas, 
suggesting that this virus is necessary, but other factors must be needed for the development 
of PELs. These factors could be EBV infection and/or immunosuppression. Recently, solid 
tumor variants with plasmablastic features have been reported and these tumors tend to be 
rapidly fatal although recent data suggest that some PEL lines are quite sensitive to inhibi-
tion of NF-κB,64 suggesting that inhibitors of NF-κB potentially can be developed as therapy 
for patients with PEL.
ARL in the Era of Highly Active Antiretroviral Therapy
Since the introduction of HAART in the 1990s, the spectrum of ARL in the context of HIV 
infection has been substantially influenced. The epidemiology of ARL has been changed 
and the outcome of these tumors has been impacted. Prior to HAART, the prognosis of ARL 
was poor because the tumors tended to be more aggressive; there was an increase in hema-
tological toxicity, and further complications occurred due to a high rate of opportunistic in-
fection in the patients.61,106 Risks for development of ARL increased as the HIV disease pro-
gressed and CD4+ T cells declined. With HAART, the prognosis of ARL has improved. There 
was a better tolerance to chemotherapy, a higher rate of complete remission, and the death 
rate has been reduced.8,39 However, HAART appears to have differential effects on different 
subtypes of ARL. A recently completed study performed by the NCI sponsored AIDS malig-
nancy consortium (AMC) demonstrated the feasibility of concomitant chemotherapy with 
HAART.94 Probably the best reported results for chemotherapy in AIDS NHL were from 
Dr. Little's group at the National Cancer Institute. Using the EPOCH regimen, the group 
achieved remission in 22 of 24 patients with a progression free survival of 23 months. These 
patients had favorable prognostic factors (median CD4+ lymphocyte count of 233 mm3/ml.119
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Enhanced toxicity of rituximab and CHOP chemotherapy was recently noted in a large mul-
ticenter trial conducted by the AMC.60 The addition of rituximab to standard-dose CHOP as 
compared to CHOP alone led to increased infectious complications and deaths attributable 
to sepsis. It is possible that delayed recovery of humoral immunity could contribute to this 
increased risk of life-threatening bacterial infections in HIV-infected patients. There have 
been several reports on the feasibility and efficacy of high-dose chemotherapy and autolo-
gous stem cell transplant for ARL.69,95 It is reasonable to assume that patients with well-con-
trolled HIV and good performance status should be considered candidates for this therapy. 
Newer approaches that may benefit patients with ARL include EBV specific cytotoxic T cells 
and agents that activate the lytic program of gamma herpesviruses, thereby sensitizing the 
tumors to antivirals.70,97
The effects of HAART on PCNSL are more dramatic than other systemic ARL. The standard 
treatment of PCNSL is whole brain irradiation, but the median survival time is still just 2.5 
months or less. With the addition of HAART to radiotherapy, several studies have shown 
an improvement in survival.56,85 In the meta analysis of 11 studies, it was estimated that the 
decline of PCNSL in the HAART era has declined by 58%. In addition, it was shown that 
HAART therapy alone has led to a regression of PCNSL.81 It is possible that with HAART, 
the restoration of cytotoxic T cells against latently expressed EBV antigens may have played 
a role in the reduction in the incidence of PCNSL, further confirming the role of EBV in the 
development of this malignancy.
In contrary to PCNSL, the effects of HAART on systemic ARL seem to be less dra-
matic.9,46 A number of studies, including a EuroSIDA study on 8,599 HIV-infected indi-
viduals, showed that all types of lymphomas were reduced after the widespread use of 
HAART in the late 1990s, and demonstrated that there was a decline in systemic lympho-
mas ranging from twofold to sevenfold since HAART.8,66,84 However, these studies also 
showed that the incidence of Burkitt's lymphomas appeared to be largely unaffected. In 
spite of the reduction of ARL in the HAART era, the risk of developing ARL in HAART-
treated HIV-infected individuals is still about 20-fold higher than in uninfected individu-
als.19 Whether this is due to the emergence of drug resistant viruses and immunosuppres-
sion, or due to prolonged mild immunosuppression and partial immune reconstitution, 
thus leading to an increase in developing cancers, is unknown. These risk factors remain 
to be elucidated.
HUMAN PAPILLOMA VIRUS-ASSOCIATED NEOPLASMS
Genital cancers have been a world-wide public health problem, especially in the context of 
HIV infection and immunosuppression. They are common malignancies found in AIDS pa-
tients. HIV infection has been shown to substantially enhance the development of cervical 
cancer and cervical cancer precursor lesions.10,78 It is also the most common female malig-
nancy in many developing countries.118
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Genital cancers and cervical intraepithelial neoplasia (CIN) have been strongly implicated 
in association with HPV infection. The first report demonstrating the association of HPV and 
cervical cancer was published by Zur Hausen et al.,123 showing that cervical cancer in the fe-
male genital tract has HPV-associated lesions. HPV infection of genital can either lead to as-
ymptomatic infection or a wide range of genital lesions, ranging from genital warts to mild 
dysplasion to invasive carcinomas. Genital lesions are often referred to as cervical intraep-
ithelial abnormalities or CIN, which is graded from I to III depending on the degree of ep-
ithelium abnormality. CIN I encompasses mild dysplasia or low-grade squamous intraepi-
thelial lesions (SIL). CIN II represents high-grade SIL with moderate dysplasia, while severe 
dysplasia is referred to as CIN III.79
In 1993, the CDC has included invasive cervical cancer as one of the AIDS-defining ill-
nesses. HIV infection has become an important risk factor for HPV infection and the de-
velopment of genital cancers. HIV and HPV infections have a number of common features; 
both are sexually transmitted diseases (STD), and there is a high prevalence of HPV infec-
tion among HIV seropositive women, especially those that are immunosuppressed with low 
CD4+ T cell counts.5,111
Up to 20% of the HIV and HPV coinfected individuals developed HPV-associated pre-
malignant lesions of the uterine cervix within 3 years of HIV infection.31 The progression 
of an untreated HPV-induced dysplasia could then lead to cervical cancer. A number of 
studies have shown that HIV positive women have 2-3 times more HPV DNA in cervico-
vaginal washings and 15 times more in anal swabs as compared to HIV negative individ-
uals.15,54,111 HIV-infected women were also shown to be much more likely to develop cer-
vical intraepithelial abnormalities. The prevalence and severity of genital tract infection in 
these women are also more pronounced.27,83 The rates of invasive cervical carcinoma are 
15-18 times higher in women with AIDS compared to the general population.32,102 Men fare 
no better—the incidence of anal cancer in men with history of anal intercourse is at 35 per 
100,000 individuals, a number equivalent to that of cervical carcinoma before the advent of 
Pap-smear screening.89,110 The mechanism by which HIV increases the risk of HPV infection 
and cervical dysplasia is likely due to immunodeficiency, resulting in the inability of the im-
mune response to control HPV infection. Indeed, cervical dysplasia increased progressively 
as the patients immune function declined, as determined by CD4+ T cell counts.52 A large, 
long-term prospective cohort studying of over 1,800 HIV positive and over 500 HIV negative 
women was carried out to determine how HIV RNA levels and CD4+ T cell counts are as-
sociated with the natural history of HPV infection.109 The results demonstrated that in HIV-
infected women, the HIV plasma viral load in combination with CD4+ T cell counts has a 
strong correlation with the detection of HPV infection and reactivation. However, there was 
only a moderate correlation between HIV coinfection and HPV persistent infection. This 
partially explains why cervical cancer rates are not even higher than what was observed in 
HIV+ infected women.
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The effects of HAART on HIV and the immune status of HIV-infected individuals are 
well established, but their effects on the course of HPV-related cervical lesions in HIV-in-
fected women are still not well established. HAART has not been shown to affect HPV de-
tection and its effects on the natural history of cervical intraepithelial neoplasia are unclear.87 
There were a number of studies examining the effects of HAART on the course of cervical 
lesions.4,51 A study by the Women's Interagency HIV Study (WIHS) group has reported an 
association of the regression of cervical lesions with HAART82 whereas others cannot.76 In 
addition, a multicenter study of HAART on the repression of cervical lesions in over 700 
women followed for over 5 years also did not show any correlation.101 However, these stud-
ies primarily focused on evaluating the effects of HAART on prevalent cervical lesions and 
the date of onset of those lesions is not known, thus it is not surprising that the outcome of 
these studies was controversial. To address these concerns, a study by Ahdieh-Grant et al.4 
determined whether HAART alters the natural history of CIN among HIV-infected women 
that were regularly followed every 6 months for 7 years. This study provided evidence that 
HAART has a modest benefit for HIV-infected women that were at risk for cervical neopla-
sia, with women receiving HAART will survive longer and have better control over cervi-
cal HPV infection and low-grade squamous intraepithelial lesions. However, HAART does 
not seem to lead to a complete reconstitution of the immune system for it to control HPV, 
the rates of regression among HIV-infected women receiving HAART remained lower than 
HIV-infected women that were never on HAART or among HIV-uninfected women. Thus, 
there is a need to actively seek and treat CIN in HIV-infected women, including those that 
are responding to HAART.
HODGKIN'S DISEASE
Hodgkin's disease (HD) or Hodgkin's lymphoma has not been classified as an AIDS-de-
fining illness but HIV-related HD is also increasing in the context of HIV infection, and is 
clearly related to the immunosuppression in the infected patients.42,47 Almost all HIV-re-
lated HD are EBV positive. The clinical presentations of HD in HIV-infected individuals are 
unique as compared to uninfected individuals, patients are more likely to have more ad-
vanced disease stage, extranodal involvement, and often involve bone marrow.25, 105, 115
Prior to the HAART era, the treatment outcome for HIV HD is poor, with a medium sur-
vival rate between 1 and 2 years. A clinical trial on treatment using doxorubicin, bleomcin, 
vinblastine, and dacarbazine on AIDS patients showed severe hematologic toxicity and a 
poor survival rate of only 1.5 years.73 More recently the outcome of treatment in combination 
with HAART appears to be improving, patients treated with HAART and responded to the 
treatment within 2 years of the development of HD have improved survival rates compared 
to those that are not responders.38,55 The use of HAART in combination with chemotherapy 
has substantially improved both the response rate and the survival time. In a trial on using
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HAART and a combination of bleomycin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine, procarbazine, and prednisone (BEACOPP), 9 out of 12 treated patients have com-
plete remission after a medium follow-up of 49 months.49 These studies suggest that HAART 
in combination with conventional chemotherapy will be beneficial for patients with HD, 
whether the effect is due to the restoration of the immune response in HIV-infected individ-
uals or due to the effects of EBV remained to be determined.
CONCLUSION
AIDS malignancies have been recognized as a major complication of the HIV disease 
course, and the high mortality rate in AIDS patients is in part due to this complication. A 
number of factors have been implicated to be playing a role in the increase incidence of 
malignancies in AIDS patients. These factors include immunosuppression and a deficient 
immune surveillance by T cells in eliminating the transformed cells; viral cofactors such as 
EBV and KSHV have also been associated with malignant transformation of the infected 
cells. The prognosis of ARL in HIV-infected individuals was extremely poor prior to the 
HAART era, but the advent of HAART, there was a dramatic improvement in the progno-
sis of ARL in these patients. The survival rate has improved, especially for those ARL that 
were found to be associated with herpesviruses such as EBV and KSHV There were a sub-
stantial decrease in the number of cases of KS and NHL, in association with HAART, and 
the decrease in incidence appear to be independent of CD4 counts, substantiating the no-
tion that coinfecting viruses may be playing a role in the disease. Most newly diagnosed 
cases of KS are patients that are either drug naive or have virological failure upon treat-
ment. In spite of the improvement in prognosis, HAART alone is inadequate for the major-
ity of the antiviral naive patients. A combination of HAART and conventional chemother-
apy appears to be most effective. Moreover, the positive effects of HAART on some ARL 
and KS are not consistently observed for HPV-associated malignancies, including cervi-
cal and anal cancers.
Given the prolong survival rate of HIV-infected individuals with HAART, it is likely that 
ARL will continue to pose a challenge in the AIDS epidemic. HAART treatment, even though 
appears to be effective, still only leads to partial immune reconstitution. Prolonged immuno-
suppression is likely to lead to a resurgence of AIDS-associated cancers. In addition, HAART 
is still not widely available in parts of the world where AIDS has the greatest impact, such 
as the African continent. It is expected that AIDS-associated cancers will continue to pose a 
major challenge in the population for quite a while. Thus, more understanding on the role of 
oncogenic viral cofactor in the disease will be of great significance. ARL represents an inter-
section of virology, immunology, and tumor biology. A better understanding of the disease, 
the immune response, will provide useful information for the development of novel therapy 
and provide insights into cancer biology beyond the AIDS epidemic.
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